Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial (original) (raw)

References

1. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103:1461–1468. doi:10.1093/jnci/djr291
   Article PubMed CAS Google Scholar
2. Bennis F, Favre G, Le Gaillard F, Soula G (1993) Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 55:640–645
   Article PubMed CAS Google Scholar
3. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23:8606–8612
   Article PubMed Google Scholar
4. Borgquist S, Djerbi S, Ponten F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirstrom K (2008) HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 123:1146–1153
   Article PubMed CAS Google Scholar
5. Borgquist S, Jogi A, Ponten F, Ryden L, Brennan DJ, Jirstrom K (2008) Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res 10:R79. doi:bcr214610.1186/bcr2146
   Article PubMed Google Scholar
6. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR (2007) Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev 16:416–421
   Article PubMed CAS Google Scholar
7. Brennan DJ, Laursen H, O’Connor DP, Borgquist S, Uhlen M, Gallagher WM, Ponten F, Millikan RC, Ryden L, Jirstrom K (2011) Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. Breast Cancer Res 13:R12. doi:bcr282010.1186/bcr2820
   Article PubMed CAS Google Scholar
8. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC (2006) Breast cancer growth prevention by statins. Cancer Res 66:8707–8714
   Article PubMed CAS Google Scholar
9. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, Margolis KL, Paskett ED, Vitolins MZ, Furberg CD, Chlebowski RT (2006) Statin use and breast cancer: prospective results from the Women’s Health Initiative. J Natl Cancer Inst 98:700–707. doi:10.1093/jnci/djj188
   Article PubMed CAS Google Scholar
10. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10–19
    PubMed CAS Google Scholar
11. Clendening JW, Pandyra A, Boutros PC, El Ghamrasni S, Khosravi F, Trentin GA, Martirosyan A, Hakem A, Hakem R, Jurisica I, Penn LZ (2010) Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci USA 107:15051–15056. doi:091025810710.1073/pnas.0910258107
    Article PubMed CAS Google Scholar
12. Clendening JW, Penn LZ (2012) Targeting tumor cell metabolism with statins. Oncogene. doi:10.1038/onc.2012.6
    PubMed Google Scholar
13. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM (2006) Statins and cancer risk: a meta-analysis. JAMA 295:74–80
    Article PubMed CAS Google Scholar
14. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942. doi:10.1038/nrc1751
    Article PubMed CAS Google Scholar
15. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656–1664. doi:10.1093/jnci/djr393
    Article PubMed CAS Google Scholar
16. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167–170
    Article PubMed CAS Google Scholar
17. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951s–958s
    PubMed CAS Google Scholar
18. Duncan RE, El-Sohemy A, Archer MC (2005) Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin. Cancer Lett 224:221–228
    Article PubMed CAS Google Scholar
19. Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhala N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 7:e29849. doi:10.1371/journal.pone.0029849
    Article PubMed CAS Google Scholar
20. Endo A (1992) The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569–1582
    PubMed CAS Google Scholar
21. Endo A, Kuroda M, Tanzawa K (1976) Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72:323–326
    Article PubMed CAS Google Scholar
22. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ (2010) Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 119:137–144. doi:10.1007/s10549-009-0507-x
    Article PubMed CAS Google Scholar
23. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425–430
    Article PubMed CAS Google Scholar
24. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ (2004) The risk of cancer in users of statins. J Clin Oncol 22:2388–2394
    Article PubMed CAS Google Scholar
25. Gruenbacher G, Gander H, Nussbaumer O, Nussbaumer W, Rahm A, Thurnher M (2010) IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56 + dendritic cells. Cancer Res 70:9611–9620. doi:10.1158/0008-5472.CAN-10-1968
    Article PubMed CAS Google Scholar
26. Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–33. doi:10.1056/NEJM198807073190105
    Article PubMed CAS Google Scholar
27. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V (2012) A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 131:915–924. doi:10.1007/s10549-011-1858-7
    Article PubMed CAS Google Scholar
28. Joo JH, Jetten AM (2010) Molecular mechanisms involved in farnesol-induced apoptosis. Cancer Lett 287:123–135. doi:10.1016/j.canlet.2009.05.015
    Article PubMed CAS Google Scholar
29. Kaneko I, Hazama-Shimada Y, Endo A (1978) Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase. Eur J Biochem 87:313–321
    Article PubMed CAS Google Scholar
30. Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51:3602–3609
    PubMed CAS Google Scholar
31. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17:1028–1033
    Article PubMed CAS Google Scholar
32. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M (2000) Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31:2442–2449
    Article PubMed CAS Google Scholar
33. Lee SJ, Ha MJ, Lee J, Nguyen P, Choi YH, Pirnia F, Kang WK, Wang XF, Kim SJ, Trepel JB (1998) Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem 273:10618–10623
    Article PubMed CAS Google Scholar
34. Lennernas H (2003) Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 42:1141–1160
    Article PubMed Google Scholar
35. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110:285–288
    PubMed CAS Google Scholar
36. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235. doi:10.1007/s10549-006-9242-8
    Article PubMed Google Scholar
37. Mo H, Elson CE (2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229:567–585
    CAS Google Scholar
38. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367:1792–1802. doi:10.1056/NEJMoa1201735
    Article PubMed CAS Google Scholar
39. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat. doi:10.1007/s10549-012-2223-1
    Google Scholar
40. Romero Q, Bendahl PO, Klintman M, Loman N, Ingvar C, Ryden L, Rose C, Grabau D, Borgquist S (2011) Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer 11:341. doi:1471-2407-11-34110.1186/1471-2407-11-341
    Article PubMed CAS Google Scholar
41. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335:1001–1009. doi:10.1056/NEJM199610033351401
    Article PubMed CAS Google Scholar
42. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301–1307. doi:10.1056/NEJM199511163332001
    Article PubMed CAS Google Scholar
43. Spyratos F, Ferrero-Pous M, Trassard M, Hacene K, Phillips E, Tubiana-Hulin M, Le Doussal V (2002) Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94:2151–2159. doi:10.1002/cncr.10458
    Article PubMed CAS Google Scholar
44. Thurnher M, Nussbaumer O, Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18:3524–3531. doi:10.1158/1078-0432.CCR-12-0489
    Article PubMed CAS Google Scholar
45. Undela K, Srikanth V, Bansal D (2012) Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 135:261–269. doi:10.1007/s10549-012-2154-x
    Article PubMed CAS Google Scholar
46. Wejde J, Blegen H, Larsson O (1992) Requirement for mevalonate in the control of proliferation of human breast cancer cells. Anticancer Res 12:317–324
    PubMed CAS Google Scholar
47. Yachnin S, Mannickarottu V (1984) Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells. Blood 63:690–693
    PubMed CAS Google Scholar

Download references